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Abstract: Of the approximately 6 million pregnancies in the United States each year,
almost half are unintended. Of these unintended pregnancies, approximately four in ten will
end in abortion. Plan B emergency contraception is a drug that has the potential to reduce
the number of abortions performed each year in half. Despite contentions from various
religious and political sects, Plan B is not an abortifacient. It acts by preventing a pregnancy
from starting rather than terminating a pregnancy that is already established. On December
16, 2003, a panel of medical and scientific experts gathered by the Food and Drug
Administration (FDA), voted overwhelmingly to approve over-the-counter (OTC) status for
Plan B emergency contraception for child -bearingwomen of all ages. In an unprecedented
move, high level FDA officials rejected the panel’s recommendation and issued a Not
Approvable letter citing a lack of data concerning the safety of Plan B for younger
adolescents. In a subsequent application for Plan B OTC status with age restrictions, the FDA
again rejected OTC approval noting various marketing, enforcement, and labeling concerns.
To illustrate the level of political interference in what should have been a medical and
scientific decision, this manuscript compares the “switch” of Plan B from prescription to OTC
status in the United States with the process in France, the United Kingdom, and Canada. The
governmental, political, and social forces affecting the switch are analyzed. Examination of
survey results from the studied countries reveal that non-prescription emergency
contraception can be safely self-administered in reproductive females of all ages, and does
not result in an increase of risky sexual practices among those women. Although, on August
24, 2006, the FDA finally granted approval for OTC access to Plan B for women aged
eighteen years and older, adolescent women, arguably the group who could most benefit from
OTC access, was once again denied. In the realm of female reproductive health,
conservative politics continues to trump sound medical and scientific judgment.
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1 Physicians for Reprod. Choice and Health® (PRCH) & Guttmacher Inst., An Overview of Abortion in the United States,
May 2006, http://www.guttmacher.org/prsentations/abort_slides.pdf. The PRCH is a national physician-led organization
committed to enhancing reproductive health and freedom. Id. The Alan Guttmacher Institute is a nonprofit organization
that promotes sexual and reproductive health. Id.
2 Id.
3 Id. In 2002, approximately 2% of all women in the U.S. aged fifteen to forty-four had an abortion. Id.
4 See id.
5 Rachel K. Jones et al, Contraceptive Use Among U.S. Women Having Abortions in 2000-2001, 34 PERSP. SEXUAL
REPROD. HEALTH 294, 300 (2002), available at http://www.guttmacher.org/pubs/journals/3429402.pdf; see also
American Academy of Pediatrics Policy Stmt., infra note 26, at 1038 (stating the decline in birth rates from 1994 to
2000, for teens aged fifteen to seventeen, reflected a higher rate of reported abstinence, more consistent use of standard
forms of birth control, and use of EC).
6 Barr Pharm, Inc., Health Policy Issue Brief, Emergency Contraception Meets Significant Medical Need: Education
and Access are Critical Issues, www.barrlabs.com/overview/government/RRL_pp-planb.pdf (last assessed July 22,
2006).
7 Food & Drug Admin., Transcript of Meeting, United States of America Food and Drug Administration Center for Drug
Evaluation and Research, Nonprescription Drugs Advisory Committee (NDAC) in Joint Session with the Advisory
C o m m i t t e e f o r R e p r o d u c t i v e H e a l t h D r u g s ( A C R H D ) , ( D e c . 1 6 , 2 0 0 3 ) ,
http://www.fda.gov/ohrms/dockets/ac/03/transcripts/4015T1.htm.
8 Letter from Steven Galson, Acting Dir., Ctr. for Drug Evaluation and Res., FDA, to Joseph A. Carrado, Senior Dir.,
Reg. Affairs, Barr Lab. (May 7, 2004), http://www.fda.gov/cder/drug/infopage/planB/planB_NALetter.pdf.
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INTRODUCTION
There is a drug that has the capability of cutting the number of abortions performed each year
in half. Imagine if women of all ages could better control their reproductive health through over-the-
counter (OTC) access to that drug. In 2001, of the 6.4 million pregnancies in the United States (U.S.),
almost half (3.1 million) were unintended.1 Of these unintended pregnancies, approximately four in
ten ended in abortion.2 In fact, abortion is considered one of the most common surgical procedures
in the U.S., estimated to affect twenty-one out of every 1000 American women aged fifteen to forty-
four years.3 Since 1980, the abortion rate has been declining, and the development of emergency
contraception (EC) is thought to be one of the primary reasons behind this fall.4 In fact, the Alan
Guttmacher Institute estimated that EC may have averted as many as 51,000 abortions in the year 2000
alone.5
The timing of the administration of EC is critical to its success. Since efficacy is increased
if the medication is started within the first twenty-four hours after unprotected intercourse,6 ready
access to EC is imperative. OTC availability of EC improves its accessibility. On December 16,
2003, the Independent Joint Advisory Committee of the Food and Drug Administration (FDA) voted
overwhelmingly to “switch” the emergency contraception, Plan B, from prescription status to OTC
status.7 Less than five months later, in an unconventional move, the Acting Director of the FDA’s
Center for Drug Evaluation and Research (CDER) issued a statement denying the OTC
recommendation.8 In explanation of this action, the director cited a lack of “adequate data to support
a conclusion that Plan B can be used safely by young adolescent women for emergency contraception
9 Id.
10 Food & Drug Admin., Transcript of Meeting, supra note 7.
11 Jeffrey M. Drazen et al, The FDA, Politics, and Plan B, 350 NEW ENG. J. MED. 1561, 1561 (2004), available at
http://www.content.nejm.org/(search”Plan B’, then follow “The FDA, Politics, and Plan B” hyperlink); see generally
Part V sec. C; see also Sue S.T. Lo et al, Effect of Advanced Provision of Emergency Contraception on Women’s
Contraceptive Behavior: A Randomized Controlled Trial, 19 HUMAN REPROD. 2404, 2408-2409 (2004) (demonstrating
that giving women an advance supply of EC pills does not lead to repeated use or affect their use of regular, more
effective, birth control).
12 The original manufacturer application for Plan B OTC status was submitted April 16, 2003 by Women’s Capital
Corporation. U.S. Gov’t Accountability Office, infra note 165, at 15; see News Release, Barr Lab., Inc., Barr Completes
Acquisition of Women’s Capital Corporation and Plan B Emergency Contraception ,
http://www.go2ec.org/pdfs/BarrCompletesAcquisition.pdf (last accessed July 30, 2006) (indicating Barr Pharmaceuticals
acquired marketing rights for Plan B on February 26, 2004).
13 Letter from Steven Galson to Joseph A. Carrado, supra note 8.
14 Id.
15 Letter from Lester M. Crawford, Comm’r of Food & Drugs, Food & Drug Admin., to Joseph A. Carrado, Senior
Dir., Reg. Affairs, Duramed Research, Inc., NDA 21-045/S-011 (Aug. 26, 2005),
http://www.fda.gov/cder/drug/infopage/planB/Plan_B_letter20050826.pdf; see also 21 C.F.R. Part 310, infra note
191. The FDA has interpreted the language of 503(b)(1) of the Federal Food, Drug, and Cosmetic Act to allow
marketing of the same active ingredients in a prescription and an OTC product as long as a meaningful difference
exists between the two that makes one product safe only by prescription. Id. Until Plan B, the FDA had not allowed
marketing of the same active ingredient in a prescription product for one population and an OTC product for another.
Id. A rulemaking would have codified the FDA’s interpretation of 503(b), but could have caused an indefinite delay
on the Plan B decision. Id.
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without the professional supervision of a practitioner . . . .”9 Despite finding that the data was
overwhelmingly supportive of the conclusion that Plan B is safe and effective for all women of child-
bearing age when obtained without a prescription,10 and that studies demonstrated that ready access
to EC did not promote risky sexual behavior,11 the FDA denied the OTC switch.
Responding to the FDA’s concerns regarding the effect of Plan B on adolescents, Barr
Laboratories12 (Barr) amended their application and requested a dual label for Plan B.13 Under the
dual label, Plan B would be sold to women OTC for ages sixteen and older and prescription-only for
those under sixteen years.14 However, the FDA again delayed making a decision on this proposal
citing marketing and enforcement difficulties with the dual label, requesting a sixty day public
comment phase to consider the need for initiating “rulemaking.”15 These persistent delays angered
both politicians and the public and lent credence to the charge that conservative politics had trumped
medical and scientific decision-making.
This manuscript analyzes the governmental regulations, political forces, and public responses
to the switch of Plan B, from prescription to OTC in the U.S. To enhance understanding of the
political and societal forces at work in the U.S., a comparative analysis of the switch of EC from
prescription to non-prescription in France, the United Kingdom (U.K.), and Canada is made. Part One
of this article describes the composition of Plan B and reviews its mode of action. The modus
operandi of Plan B is of particular importance since much of the political and social hostility
surrounding the medication hinges on the perception of whether it is abortifacient or contraceptive.
Part Two compares the regulatory processes and public reactions of the switch of EC from
prescription to non-prescription in France, the U.K., and Canada. Part Three highlights the FDA
regulatory body itself and explores the question of whether the FDA has been “politically stacked”
by conservative appointees. Part Four describes the rocky road to OTC status for Plan B in the U.S.
and whether conservative politics interfered with medical and scientific judgment. Part Five analyzes
16 Dorland’s Illustrated Medical Dictionary 5 (30th ed. 2003) (defining abortifacient as causing abortion); see also
Definition ofAbortifacient, MedicineNet.com, http://www.medterms.com/script/main/art.asp?articlekey=10912 (defining
an abortifacient as a substance that causes pregnancy to end prematurely and causes an abortion) (last accessed July 30,
2006).
17 Plan B official website, What is Emergency Contraception?,
http://www.go2planB.com/ForConsumers/AboutPlanB/AboutEmergencyContraception.aspx (last accessed June 14,
2006). Unprotected sex is described as the act of using no birth control, using a method of birth control that did not
work (such as a condom breaking), or the act of nonconsensual intercourse (rape). Id.
18 Id.
19 Food & Drug Admin. Ctr. for Drug Evaluation and Res., FDA’s Decision Regarding Plan B: Questions and Answers,
http://www.fda.gov/cder/drug/infopage/planB/planBQandA.htm (May 7, 2004). Prior to FDA approval of prescription
Plan B, medical providers could prescribe elevated doses of routine birth control pills as a post-coital contraceptive.
Grimes & Raymond, infra note 25, at 181 (listing levonorgestrel-containing EC options in U.S.).
20 Plan B package labeling. The designation of Plan B as a “morning after pill” is actually a misnomer, for the first dose
of Plan B should be taken within the first seventy-two hours after unprotected intercourse, not necessarily the “morning
after.” Id.
21 Id.
22 Drazen et al, supra note 11, at 1561.
23 Id.
24 Alastair J.J. Wood et al, A Sad Day for Science at the FDA, 353 NEW ENG. J. MED 1197, 1197 (2005)
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the survey results describing the pros and cons of non-prescription EC and the effects of EC on the
sexual behaviors of women in the studied countries. In Part Six, the state and grassroot efforts that
were used to by-pass the conservative stranglehold on OTC approval of Plan B are reviewed. Finally,
in Part Seven, the current status of Plan B and the expectations for its future are examined.
I. WHAT IS PLAN B?
In order to understand Plan B and the controversy that surrounds the drug, it is crucial to
examine the mode of action of the medication and the significance that various religious and scientific
factions place upon that mode. At the root of the controversy is the question of whether EC is
contraceptive or abortifacient.16
The manufacturer of Plan B defines the medication as an emergency contraception that is used
to prevent pregnancy after unprotected sex or contraceptive failure.17 The manufacturer emphasizes
that Plan B is intended for emergency contraceptive use only and is not to be used in lieu of routine
birth control.18 Plan B consists of two 0.75mg. pills of levonorgestrel, a synthetic progestin contained
in many current birth control pills.19 The first pill should be taken as soon as possible within the first
seventy-two hours following unprotected intercourse.20 The second pill should be taken twelve hours
25 David A. Grimes & Elizabeth Raymond, Emergency Contraception, 137 ANNALS OF INTERNAL MED. 180, 182 (Aug.
6, 2002).
26 Comm. on Adolescence, Pol’y Statement, Emergency Contraception, 116 PEDIATRICS 1038, 1040 (2005).
27 Grimes & Raymond, supra note 25, at 181-182.
28 Hapangama et al, The Effects of Peri-Ovulatory Administration of Levonorgestrel on the Menstrual Cycle, 63
CONTRACEPTION 123, 128 (2001). For further analysis, see Population Briefs, Globilization is Transforming
Adolescence in the Developing World, 11 Rep. Population Council Res. (May 2005) (describing luteinizing hormone
as the stimulus for the ovulatory process), available at http://www.popcouncil.org/pdfs/popbriefs/pbmay05.pdf.
29 Yuzpe et al, Post Coital Contraception – A Pilot Study, 13 J. REPROD. MED. 53, 57 (Aug. 1974). For further
discussion, see also Comm. on Adolescence, Pol’y Statement, supra note 26, at 1040; see also Hapangama, supra note
28, at 128 (where one study subject experienced slight vaginal bleeding possibly suggesting an endometrial change).
30 Durand et al, On the Mechanisms of Action of Short-Term Levonorgestrel Administration in Emergency
Contraception, 64 CONTRACEPTION 227, 233 (2001).
31 Id.
32 Planned Parenthood official website, Emergency Contraception, http://www.plannedparenthoodorg (search
“emergency contraception”) (last accessed June 18, 2006).
33 See transcript from CBS News, The Debate Over Plan B, Broadcast (June 11, 2006), available at
http://www.cbsnews.com/stories/2005/11/22/60minutes/printable106894.shtml.
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after the first.21 If Plan B treatment is initiated within the first twenty-four hours after unprotected sex,
the resultant pregnancy rate is as low as 0.4%.22 If treatment is not started until forty-eight to seventy-
two hours after unprotected sex, the pregnancy rate climbs to 2.7%.23 Since EC is often needed on the
evenings or weekends (times with limited access to physician supervised care) contraceptive efficacy
could be increased by increasing accessibility of EC.24 A prescription requirement for Plan B only
creates delays.
According to the American College of Obstetricians and Gynecologists (ACOG), EC prevents
a pregnancy from starting rather than interrupting an already established pregnancy.25 Plan B’s
method of action is similar to that of other oral contraceptives in that it primarily inhibits ovulation,
disrupts development of the ovarian follicle, and/or interferes with the maturation of the corpus
luteum,26 depending on the time in the menstrual cycle when the medication is taken.27 In a study
evaluating the effects of levonorgestrel on pre-ovulatory women, blood tests indicated that Plan B
suppressed ovulation by suppressing luteinizing hormone.28 However, several studies have shown a
biochemical or tissue alteration in the uterine lining after treatment with EC, suggesting that it could
impair the endometrium’s receptivity to a fertilized egg.29 Other studies have demonstrated no such
changes.30 Whether changes noted would be sufficient to impair implantation has not been
established.31 What is known is that Plan B, which is a progestin-only contraceptive, is supportive of
pregnancy and will not terminate or negatively affect an already established pregnancy.32
Much of the controversy surrounding Plan B began when anti-abortion rights groups labeled
the medication an abortifacient and not a contraceptive.33 In contrast to the ideology of the scientific
and medical community, which define conception as beginning at the moment of implantation of the
34 See Charles E. Rice, Abortion, Euthanasia, and the Need to Build a New ‘Culture of Life’, 12 NOTRE DAM J.L.
ETHICS & PUB. POL’Y 497, 511 (1998).
35 See Comments from Pro-Life Leaders, FDA Approval of the “Morning-After-Pill,” Pro-Life Outreach Source,
http://www.cogforlife.org/morningafterpill.htm (last accessed May 17, 2006); see also Elizabeth Spahn & Barbara
Andrade, Mis-Conceptions: The Moment of Conception in Religion, Science, and Law, 32 U.S.F.LREV. 261, 264 (1998).
Although it’s a widely held belief that the Catholic Church has always maintained that human life began at the moment
of fertilization, that assumption is incorrect. Id. Before 1869, the Church held the position that life began at the moment
of “ensoulment” (when the soul entered the developing body), somewhere around the third to fourth month of gestation.
Id. For further analysis, see JAFFE ET AL,ABORTION POLITICS,THECATHOLICCONNECTION,73-85(Robert A. Rosenbaum
& Carolyn Nagy eds., Alan Guttmacher Inst., 1981) (discussing the political role of the Catholic Church dealing with
abortion.
36 Comment from Pro-Life Leaders, FDA Approval of the “Morning-After-Pill,” supra note 35.
37Ayelish McGarvey, Dr. Hager’s Family Values, THE NATION (May 30, 2005), available at
http://www.thenation.com/doc/20050530/mcgarvey; see also Food & Drug Admin., Transcript of Meeting,, supra note
7. Dr. Hager argued for a clear statement on the Plan B package label that would indicate that there is a potential effect
on the endometrium lining from the medication. Id.
38 Food & Drug Admin., Transcript of Meeting, supra note 7. The abortion argument would have carried little weight
since abortion was made legal in the U.S. on January 22, 1973 in Roe v. Wade, 410 U.S. 113 (1973), and it is not the
purpose of the FDA to dictate morality.
39 Food & Drug Admin, Transcript of Meeting, supra note 7.
40 McGarvey, supra note 37.
41 PR Newswire, Plan B® Emergency Contraceptive Granted Non-Prescription Status in Canada,
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/04-20-2005/0003439714&EDATE=
(last accessed June 18, 2006).
42 Planned Parenthood, A Brief History of Emergency Hormonal Contraception (2005),
http://www.ppfa.org/pp2/portal/files/portal/medicalinfo/ec/fact-emergency-contraception-history.xml.
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fertilized egg into the uterine lining,34 the Roman Catholic Church defines conception as beginning
at the moment of fertilization.35 Therefore, according to the Church, a medication that has the
potential to cause the uterine lining to become unreceptive toward the implantation of an embryo is
abortifacient.36
Dr. David Hager, a conservative religious rights activist who served on the FDA advisory
committee reviewing the application for the OTC switch, had previously classified Plan B as
abortifacient despite inconclusive evidence that it could inhibit implantation of a fertilized egg into
the endometrial lining.37 However, when Dr. Hager argued against OTC approval for Plan B at the
FDA advisory meeting, he did not voice an ethical opposition to the medication based on the abortion
theory, but rather emphasized his concerns regarding Plan B and its effect on adolescents.38 Dr. Hager
stated, “I’m not in favor of promotion of a product that would increase sexual activity among
teenagers.”39 Since that comment, fellow committee members have labeled Hager’s concern a
‘“political fig leaf’”40 used to cover the conservative Christian view that EC is abortifacient.
II. THE SWITCH OF EMERGENCY CONTRACEPTION FROM
PRESCRIPTION TO NONPRESCRIPTION IN FRANCE,
THE UNITED KINGDOM, AND CANADA
Restrictions on dispensing EC are easing across the globe. EC is available worldwide in 102
countries.41 Women in forty-two countries can obtain emergency contraception without a
prescription.42 In comparison, the U.S. has moved at a snail’s pace in providing EC options to its
43 Heather Boonstra, Promoting Contraceptive Use and Choice: France’s Approach to Teen Pregnancy and Abortion,
3 GUTTMACHER REP. ON PUB. POL’Y (June 2000), available at http://www.guttmacher.org/pubs/tgr/03/3/gr030303.pdf.
44 Id.
45 Id.
46 Id.
47 Caroline Moreau et al, The Impact of Pharmacy Access to Emergency Contraceptive Pills in France, 73
CONTRACEPTION 602, 602 (2006). The decision to dispense EC in the schools was suspended by a court order between
June 2000 and March 2001. Id. The Council of State (France’s highest administrative court) overruled the decision to
make EC available in the schools citing a 1967 law (the Contraception Law of 1967) stating that hormonal contraception
could be distributed only under prescription by pharmacies. Planned Parenthood, supra note 42. In October 2000, the
French Parliament amended the law allowing school nurses to once again dispense EC. Id.
48 Heather Boonstra,, Emergency Contraception: Steps Being Taken to Improve Access, 5 GUTTMACHER REP. ON PUB.
POL’Y 10, 12 (Dec. 2002) available at http://www.guttmacher.org/pubs/tgr/p5/5/gr050510.pdf.
49 Id.
50 In 1974, the age for consensual sex in France was lowered from age twenty-one to eighteen. Nathalie Bajos &
Sandrine Durand, Teenage Sexual and Reproductive Behavior in Developed Countries: Country Report for France, Alan
Guttmacher Inst., http://www.guttmacher.org/pubs/summaries/france_teen.pdf.
51 Boonstra, supra note 43.
52 Id.
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female residents. To better understand the FDA regulatory process and the consequences resulting
from the agency’s delay of action on Plan B, it is helpful to examine the experiences encountered in
France, the U.K., and Canada during the process of making EC available non-prescription.
A. FRANCE
In June 1999, in response to a static abortion rate, the French government switched the status
of Norlevo, the French EC drug, from “prescription” to “available on request from a pharmacist.”43
Although the French abortion rate is one-third that of the U.S., government officials were concerned
because the numbers were remaining steady and not declining.44 In order to reduce abortion numbers
and revitalize contraceptive policies, France initiated an aggressive contraceptive education campaign
called ‘“La contraception, a vous de choisir la voitre,”’ or ‘“Contraception: It’s up to you to choose
your own.’”45 At the heart of this campaign was a media blitz which provided information about the
myriad of contraceptive choices available for single women, couples who have completed
childbearing, and adolescents.46 Furthering this initiative, France announced a new policy which
would allow school nurses to provide EC in junior and high schools, grades six through twelve.47 In
addition, financial incentives have been utilized to enhance EC access. In France, a woman can obtain
a non-physician prescribed EC at full cost directly from a pharmacy, or at thirty-five percent of the
cost with a prescription.48 There is no cost for EC for females under the age of eighteen when the EC
is obtained from a school nurse, pharmacist, or family planning clinic.49
This aggressive contraceptive campaign has enjoyed wide support fromFrench citizens. Open
about the concept of sexuality,50 the French government’s response to teenage pregnancy and abortion
has focused on enhanced education and improved access to contraception.51 In contrast, U.S.
policymakers have tried to address high abortion and teenage pregnancy rates by promoting abstinence
or by making abortions harder to get.52 As lamented by Jacqueline Darroch, the vice president of
research at The Alan Guttmacher Institute, “The gap between our countries’ approaches to teen sexual
behavior is reflected in a wide gap in our teen pregnancy and abortion rates. It is unfortunate that in
the United States, we lag so far behind . . . We don’t even come close to what’s been achieved in
53 Id.
54 See Boonstra, supra note 48, at 12.
55 Boonstra, supra note 43.
56 Id.
57 Id.
58 Katie D. Schenek, Emergency Contraception: Lessons Learned from the UK, 29 J. FAM. PLAN. AND REPROD. HEALTH
CARE 35, 35 (2003).
59 Id.
60 Alasdair Breckenridge & Kent Woods, Medicine’s Regulations and the Pharmaceutical Industry, 331 BRIT. MED.
J. 834, 834 (2005), available at
http://bmj.bmjjournals.com/cgi/reprint/331/7520/834?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=Medici
nes+regulation&searchid=1&FIRSTINDEX=0. The duties of the agency are to protect pubic health, to provide
adequate information on medicines to the public, and to refrain from imposing unnecessary restrictions that would
prevent public access to innovative medicines. Id.
61 Med. and Healthcare Products Reg. Agency, Legal Status and Reclassification, http://www.mhra.gov.uk (search
“drug classification status,” then “Licensing of medicines: Legal status and reclassification of medicines” hyperlink).
“P” status indicates that a medicine has met a safety standard which indicates it can be sold or supplied under the
supervision of a pharmacist without a physician’s prescription. Id.
62 Id. In order to switch to “P” status, the medicine’s sponsor must show that the medication can be used safely without
the supervision of a doctor, the medicine is not a danger to human health, and it does not have a record of incorrect use.
Id.
63 S.R. Killick & G. Irving, A National Study Examining the Effect of Making Emergency Hormonal Contraception
Available Without a Prescription, 19 HUMAN REPRODUCTION 553, 553 (2004).
64 Id.
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France.”53
However, the French contraceptive campaign was not without opposition. Activists affiliated
with the “profamily” movement regarded the action of Norlevo as “tantamount to abortion,”54 and
were openly hostile to the campaign. The drive to distribute EC in schools faced opposition with
parents fearful that the school policy would intensify an already liberal French attitude about sex,
contraception, and abortion.55 Other objections included the concern that the program did not
encourage parental participation, that easier access to EC would increase sexually transmitted diseases
(STD’s), and that EC would be used in lieu of regular birth control.56 But despite being a Catholic
dominated country, no organized opposition movement ever materialized.57
B. THE UNITED KINGDOM
The U.K. was the second European country, following France, to make EC available directly
from a pharmacist .58 At twenty-four pregnancies per 1000 women aged fifteen to nineteen years, the
U.K. has the highest teenage pregnancy rate in Europe – three times as high as that in France.59
The regulatory body for medicine in the U.K. is the Medicines and Healthcare Products
Regulatory Agency.60 Before a medicine can switch from “prescription only” to “pharmacy,” or “P”
status,61 the medication’s sponsor must demonstrate certain safety and efficacy standards.62 In January
2001, Levonelle-2, a progestogen-only product, was granted “P” status in the U.K. and was made
available for women over the age of sixteen years directly from a pharmacist without a prescription.63
Women under the age of sixteen continued to require a health care provider’s prescription.64 In order
to differentiate the non-prescription product from the prescription product, Schering Health Care Ltd.
(Schering) repackaged Levonelle-2 in a colorful pack with an enhanced information booklet and sold
65 Schenek, supra note 58, at 36.
66 BBC News, Morning After Pill Dose Changed, December 1, 2003, http://news.bbc.co.uk/2/hi/health/3253932.stm (last
accessed July 2, 2006). The World Health Organization conducted a large scale study which found a single dose was
safe and effective. Id. See also World Health Org., Annual Technical Rep. 2000, Executive Summary,
http://www.who.int/mipfiles/2063/mipexsum.pdf (reporting on the 1998 to 2000 multinational study involving nearly
1400 participants). The Department of Health hopes that a single dose will cut unintended pregnancies caused by women
who forget to take the second dose. Id.
67 E-mail from Andrea Solomon, Medimpex UK Ltd., (July 18, 2006, 09:23 CST) (on file with author); see also
Schering Health Care Ltd., Levonelle® 1500 Microgram Tablet,
http://www.emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=17040 (informational booklet
describing prescription-only Levonelle® 1500); see also Schering Health Care Ltd., Levonelle® One Step Tablet,
http://www.emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=15361 (informational booklet
describing non-prescription Levonelle® One Step).
68 Schenek, supra note 58, at 36-37. Prior to government approval for non-prescription access to EC, financially
deprived areas with high teenage pregnancy rates were designated as Health Action Zones (HAZ). Id. at 36. Local
health authorities in the HAZ bypassed legal restrictions and developed innovative pilot schemes to increase access to
EC through a pharmacist at no cost to the consumer. Id.
69 Id.
70 Id. at 37.
71 Id. at 38.
72 Medical/Legal Critique, Catholic Doctors Guild, A Challenge To the Legality of Supplying the ‘Morning After Pill’
(Levoneele-2) Without a Prescription, available at http://www.catholicdoctors.org.uk (search “morning after pill;” then
select “Morning After Pill – Critique” hyperlink) (last accessed June 14, 2006).
73 Killick & Irving, supra note 63, at 556; see also Schenek, supra note 58, at 38 (noting that the plaintiffs claimed
Levonelle was abortifacient and illegal under the 1861 Offences Against the Person Act (the Act)). Under the Act, it
is illegal to supply any ‘poison or other noxious thing’ with intent to cause miscarriage. Offences Against the Person Act
1861 (Aug. 6, 1861), available at http://members.aol.com/abtrbng/oatpa61.htm.
74 Schenek, supra note 58, at 38.
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it non-prescription under the name Levonelle.65 In 2005, the two-tablet Levonelle/Levonelle-2 was
phased out to bring out a single tablet pack.66 Again, the outer packaging and informational inserts
differ between the prescription and non-prescription products.67
The move to introduce age restrictions for Levonelle was unusual as there were no age
restrictions on the use of levonorgestrel-only EC’s that were prescribed by licensed physicians, nor
were there any age restrictions in the U.K. pilot studies.68 Similar to the FDA’s reasoning in the U.S.,
Schering explained the restriction by citing a lack of clinical data on adolescents and the need for
appropriate counseling to meet an adolescent’s ongoing sexual concerns.69 The act of introducing age
restrictions at an early stage in the licensing process may have represented an attempt by the
pharmaceutical company to address the anticipated moral backlash, but age restrictions have been
attacked as representing an unnecessary barrier to EC access.70
In the U.K., the switch of EC from prescription to non-prescription status was wrought with
opposition. Pro-life groups vehemently opposed the switch maintaining levonorgestrel was
abortifacient.71 The Catholic Doctors Guild released a statement saying, “[w]hat is morally relevant
is the deliberate attack upon life itself. That is clearly the intention, irrespective of the modus
operandi of the means used.”72 In addition, in May 2001, the Society for the Protection of the Unborn
Child brought a legal challenge before the High Court claiming the use of EC constituted an illegal
abortion.73 The case had potential to jeopardize all modern fertility control methods, but was
eventually dismissed by the High Court in April 2002.74
Despite the controversies, the U.K. government continued to engage in an aggressive
75 BBC News, Pupils Given MAP: Pupils at High Schools Across Worcestershire Are to Be Offered the Morning After
Pill, http://news.bbc.co.uk (search “emergency contraception”, then “Pupils Given Morning After Pill” hyperlink) (last
accessed July 30, 2006).
76 Henry Kaiser Fam. Found., U.K. To Reduce Tax on Condoms, EC, Advocates Say (March 3, 2006), kaisernetwork.org,
http://www.kaisernetwork.org/daily_reports/print_report.cfm?DR_ID=35764&dr_cat=2.
77 Id.
78 Schenek, supra note 58, at 38.
79 Canadian Women’s Health Network, Health Canada Gives Canadian Women a Plan B; Plan B “Morning After Pill”
Now Available Without a Prescription, http://www.cwhn.ca/resources/cwhn/ec.html (last accessed June 18, 2006).
80 Med. News Today, Health Canada Approves Emergency Contraceptive Plan B As OTC Drug (Apr. 22, 2005),
http://www.medicalnewstoday.com/medicalnews.php?newsid=23275. Health Canada’s criteria for non-prescription
medications include safety, self diagnosis, and narrow therapeutic range. Nonprescription Status for Emergency
Contraception, infra note 225 at 861.
81 Medical News Today, supra note 80. In accordance with Canada’s regulatory process, the public was allowed a
seventy-five day comment period before Health Canada gave final approval. Go2ec.org., infra note 83.
82 Women’s Health Matters, ‘Morning After Pill’ Available Without Prescription (Apr. 20, 2005),
http://www.womenshealthmatters.ca/news/news_show.cfm?number=429.
83 Go2ec.org., Canada, http://www.go2ec.org/Canada.htm (last accessed June 12, 2006).
84 Id.
85 Telephone interview with representative of Paladin Labs Marketing Division (conducted June 28, 2006), 1-888-376-
7830.
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campaign to reduce the teenage pregnancy rate. In addition to making EC non-prescription, the
community of Worcestershire made EC available to high school pupils without their parents’
permission.75 There is currently a proposal before Parliament to reduce the tax on condoms and EC
from 17.5% to 5%, an estimated savings to consumers of $88 million on condoms alone.76 The cost
of EC would drop from about $44 per package to approximately $39.77 Financially deprived areas
would offer Levonelle for free. 78 Since cost is a common barrier to EC access, a reduction in price
could substantially increase access.
C. CANADA
A 2004 survey revealed that 70% of Canadians agreed that Plan B should follow in the
footsteps of France and the U.K. and be made available without prescription.79 On April 19, 2005,
Canada’s national health agency, Health Canada, approved Plan B for use without a doctor’s
prescription.80 The switch was from “Schedule F,” sold only with a physician’s prescription, to
“Schedule II,” available behind the counter from a pharmacy after consultation with a pharmacist.81
Prior to the country-wide change to non-prescription status, Plan B was already sold without a
prescription through pharmacists in the provinces of Quebec, British Columbia, and Saskatchewan.82
Although the Canadian federal government determines whether a drug should be prescription
or non-prescription, each province establishes the condition for sale of non-prescription drugs.83
Although previously reported that Plan B would be sold with age restrictions in French Canada,84
Paladin Laboratories now reports that Plan B is sold without age restriction throughout the country.85
Public reaction to non-prescription access has been divided. Supporters of the OTC decision
recognize that easier access to EC will reduce abortion numbers throughout the country, while
opponents argue it will increase risky sexual behavior and become a substitute for routine birth
86 Henry Kaiser Fam. Found., Canadian Government Proposes Selling Emergency Contraception Without Doctor’s
Prescription (May 20, 2004), Kaisernetwork.org,
http://www.kaisernetwork.org/daily_reports/rep_index.cfm?DR_ID=239809.
87 Emergency Contraception Could Lower Abortion Rate, 170 CANADIAN MED. ASSOC. J. (2004); see also LifeSite,
Abortion-Causing Morning-After Pil l Approved Across Canada Without Prescription ,
http://www.lifesite.nte/1dn/2005/apr/05042002.html (quoting MaryEllen Douglas, National Organizer of Campaign Life
Coalition, saying, “The government is telling our young people to act irresponsibly sexually and then run to the
pharmacist who will provide them with a magic pill to solve their problems.”).
88 Henry Kaiser Fam. Found., supra note 86 (quoting the executive director of the Canadian Women’s Health Network
saying, “There is no compelling medical argument to require contact with a pharmacist to obtain [EC].”).
89 Med. News Today, Health Canada Approves Emergency Contraception Plan B as OTC Drug,
http://www.medicalnewstoday.com/medicalnews.php?newsid=23275 (last accessed July 30, 2006).
90 Food & Drug Admin., FDA Organization, http://www.fda.gov/opacom/7org.html (last accessed June 19, 2006).
91 Id.
92Food & Drug Admin., FDA’s Mission Statement, http://www.fda.gov/opacom/morechoices/mission.html (last accessed
June 19, 2006); see also Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 393 (d)(1) (2001) (stating the mission of
the FDA is to promote public health by assuring foods, human drugs, and veterinary drugs are safe, and public is
protected from product radiation).
93 Food & Drug Admin., History of the FDA, http://www.fda.gov/oc/history/historyoffda/default.htm (last accessed June
19, 2006).
94 Food & Drug Admin., Performance Budget Overview,
http://www.fda.gov/oc/oms/ofm/budget/2007/PDF/2ConsolidatedBIB.pdf (last accessed June 19, 2006).
95 Id.
96 Id.
97 Food & Drug Admin., FDA Organization, supra note 90.
98 Food & Drug Admin., A Brief History of the Center for Drug Evaluation and Research,
http://www.fda.gov/cder/about/history/Histext.htm (last accessed June 19, 2006).
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control.86 Catholic organizations label Plan B abortifacient,87 while some women’s health advocates
feel the government’s decision to switch Plan B to Schedule II did not go far enough.88 Health
Canada’s decision to make Plan B available without a prescription was supported by the Canadian
Pharmacists Association, the Royal College of Physicians and Surgeons, the Canadian Nurses
Association, and the Planned Parenthood Federation of Canada.89
III. THE FOOD & DRUG ADMINISTRATION: POLITICALLY STACKED?
The regulatory body for medications in the U.S. is the FDA.90 The FDA is one of eleven Public
Health agencies that falls within the jurisdiction of the Department of Health and Human Services
(HHS).91 The mission of the FDA is to protect public health “by assuring the safety, efficacy, and
security of human and veterinary drugs, biological products, medical devices, our nation’s food supply,
cosmetics, and products that emit radiation.”92
From the humble beginnings of a single chemist in the U.S. Department of Agriculture in
1862, to a current staff of approximately 9,100 employees, the scope of the FDA is enormous.93 The
FDA oversees items accounting for approximately twenty-five cents of every dollar spent by
consumers.94 Annually, this totals approximately $1.5 trillion, or 20% of all U.S. consumer
expenditures.95 The recently released FDA performance budget request for the year 2007 is
$1,947,282,000, which is $70,798,000 higher than in 2006.96
The FDA consists of eight centers, including the CDER.97 With the goal of assuring that safe
and effective drugs are available to the American public,98 the CDER regulates all matters relating to
99 Food & Drug Admin., Center for Drug Evaluation and Research Fact Book 1997, Office of Pharmaceutical Science
Generic Drug Review, http://www.fda.gov/cder/reports/cderfact.pdf (last accessed June 19, 2006).
100 New Drugs Exempted from Prescription-Dispensing Requirements, 21 C.F.R § 310.200(b) (2006).
101 Id. See also Procedures for Classifying OTC Drugs as Generally Recognized as Safe and Effective and Not
Misbranded, and for Establishing Monographs, 21 C. F. R. § 330.10 (2006) (stating a drug is suitable for OTC use
when it demonstrates a safety and efficacy profile suitable for self administration and is labeled in a manner which
can be understood by the ordinary individual).
102 21 C. F. R. § 310.200(b).
103 Citizens petition to FDA requesting OTC status for Plan B (Feb. 14, 2001), Citizen Petition, 21 C.F.R. §
10.30(e)(2)(i)(ii)(iii) (2006), available at www.c rlp.org/pdf/EC_petition.pdf.
104 Citizen Petition, 21 C.F.R. § 10.30(e)(2)(i)(ii)(iii) (2006).
105 Ann Friedman, Over the Counter Insurgency , Mother Jones ( Aug. 1, 2006),
http://www.motherjones.com/news/update/2006/08/planb_timeline.html.
1 0 6 P l a n n e d P a r e n t h o o d , M i l e s t o n e s o n R o a d t o O v e r - t h e - C o u n t e r E C ,
http:www.planneparenthood.orghttp://www.plannedparenthood.org/pp2/portal/files/portal/media/media-050830-ec-ti
meline.xml (last accessed July 30, 2006).
107 Id. Included in the application was a labeling comprehension study and an actual use study. Id. The purpose of the
one month label comprehension study was to test if consumers could understand the proposed label for Plan B. Food
& Drug Admin., Study #9728: Plan B OTC Label Comprehension Study, available at
.http://www.fda.gov/ohrms/dockets/AC/03/briefing/4015B1_06_FDA-Tab%202-2-Label%20Conprehension%20Stu
dy.doc (last accessed July 30, 2006). Overall, test subjects could understand the indication for Plan B and recognize
potential adverse reactions. Id. The purpose of the actual use study was to evaluate the subjects’ ability to select and
administer Plan B in an OTC setting. Food & Drug Admin., Executive Summary of Actual Use Study, available at
http://www.fda.gov/ohrms/dockets/AC/03/briefing/4015B1_06_FDA-Tab%202-2-Label%20Conprehension%20Stud
y.doc. The study results demonstrated the majority of subjects correctly selected and self administered Plan B. Id. Most
incorrect use was due to not taking the second pill twelve hours after the first. Id.
108 Feminist Majority Foundation, Bush Stacks FDA Panel: Ideology Trumps Medicine and Science Again (Dec. 26,
2002), http://www.feminist.org/news/newsbyte/uswirestory.asp?id=7384.
109 Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 393(d)(1) (2001).
110 Mark Kaufman, FDA’s Reliance On Unconfirmed Chiefs is Faulted, WASH. POST, Dec. 19, 2004, at A01.
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both prescription and non-prescription drugs and their generic counterparts.99
Under FDA rules and regulations, a drug shall be exempted from prescription dispensing
requirements when it has been shown “that the drug is safe and effective for use in self-medication as
directed by proposed labeling,”100 and prescription requirements are not necessary for the protection
of public health.101 Regulations further state that the process of initiating a prescription status change
may be started by the FDA Commissioner or by any interested person.102
On February 14, 2001, a group of seventy medical, public health, and other organizations filed
a citizens’ request that the FDA exempt Plan B from prescription-dispensing requirements.103 Despite
Code regulations which require the FDA to respond within 180 days by either approving the petition,
denying the petition, or providing a reason why a decision cannot be reached,104 the FDA did not
respond.105 On April 21, 2003, Women’s Capital Corporation, the maker of Plan B, filed a
supplemental new drug application (sNDA) requesting OTC status for the medication.106 Their
application contained approximately 15,000 pages of data bound in fifty-nine volumes and incorporated
research from thirty-nine clinical studies.107
In recent years, the FDA has been plagued with accusations of politically conservative
interference or stacking.108 The President has the power to appoint the Commissioner of the FDA,
subject to approval by the Senate.109 Despite the theory that requiring Senate confirmation would make
the FDA Commissioner’s role more powerful,110 as of this date, only four FDA Commissioners have
111 Food & Drug Admin., Commissioners and Their Predecessors, http://www.fda.gov/oc/commissioners/ (last accessed
June 20, 2006).
112 Gardiner Harris, Bush Picks F.D.A. Chief, But Vote Is Unlikely Soon, NY TIMES, Mar. 16, 2006, at A18, available at
2006 WLNR 4369947. For further explanation, see discussion Part VII.
113 Food & Drug Admin., Press Release, FDA Approves Over-the-Counter Access for Plan B for Women 18 and Older;
Prescription Remains Required for Those 17 and Under, http://www.fda.gov/bbs/topics/NEWS/2006/NEW01436.html
(last accessed Aug. 28, 2006).
114 Gardiner Harris, F.D.A. Approves Broader Access to Next-Day Pill, NY TIMES, Aug. 25, 2006, , available at
http://www.nytimes.com/2006/08/25/health/25fda.html?ei=5070&en=e61ea6b55f26fd92&ex=1158206400&pagewa
nted=print.
115 Alex Gordon, Comment, The Delicate Dance of Immersion and Insulation: The Politicization of the FDA
Commissioner, course requirement Harv. L. School, available at http://leda.law.harvard.edu/leda/data/536/Gordon.rtf.
Dr. Henney hoped she would be asked to remain in office, but Bush accepted her letter of resignation which had been
filed as a routine matter before Bush’s inauguration. Id.
116 Biography of Mark B. McClellan., available at
http://www.cms.hhs.gov/CMSLeadership/Downloads/McClellanMarkBio.pdf (last accessed June 20, 2006); see also
Food & Drug Admin., Mark B. McClellan – Biography, http://www.fda.gov/oc/commissioners/mcclellan.html (last
accessed June 19, 2006) (highlighting Dr. McClellan’s work history in research and in the White House).
117 Scott McClellan was White House Press Secretary for President George W. Bush from 2003 to 2006. Wikipedia,
Scott McClellan – Biography, http://en.wikipedia.org/wiki/Scott_McClellan (last accessed Aug. 6, 2006). He was
replaced by Tony Snow on April 26, 2006. Id.
118 Biography of Mark B. McClellan, supra note 116.
119 Id.
120 Christopher Lee, . . . and a Departure; McClellan toStep Down as Chief of Medicare After Overseeing Launch of
P r e s c r i p t i o n D r u g P l a n , W A S H . P O S T a t A 1 3 , a v a i l a b l e a t
http://www.washingtonpost.com/wp-dyn/content/article/2006/09/05/AR2006090500382_pf.html.
121Wikipedia, Lester Crawford – Biography, http://en.wikipedia.org/wiki/Lester_Crawford (last accessed Aug. 6, 2006).
Food & Drug Admin, Dr. Lester M. Crawford - Biography, http://www.fda.gov/oc/crawford/bio.html (last accessed June
19, 2006). Dr. Crawford had previously served as Deputy Commissioner of the FDA during a vacancy period from
February 2002 to November 2002. Id.
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been confirmed by the Senate.111 President Bush nominated current acting Commissioner, Dr. Andrew
C. von Eschenbach, for confirmation on March 15, 2006, but the final confirmation vote was delayed
pending the FDA decision regarding OTC Plan B.112 With the announcement on August 24, 2006, that
the FDA had approved OTC access for Plan B for women eighteen years and older,113 Senators Hillary
Rodham Clinton and Patty Murray announced they would lift their hold on Dr. von Eschenbach’s
confirmation.114
Shortly after George Bush’s inauguration, Dr. Jane Henney, the Commissioner of Food and
Drugs (and a Clinton appointee), resigned115 and was replaced by Dr. Mark McClellan,116 the brother
of former White House Press Secretary, Scott McClellan.117 Dr. McClellan served as Commissioner
of the FDA from November 2002 to March 2004 and is ‘“widely regarded as one of the most effective
of all Bush appointees.”’118 Confirmed by a unanimous vote of the Senate to the position of
Administrator of the Centers for Medicare & Medicaid Services on March 25, 2004, Dr. McClellan left
the FDA and oversaw the massive task of implementing Medicare’s new prescription drug plan.119
After two years directing the nation’s two largest public health insurance programs, Dr. McClellan
announced his resignation on September 5, 2006.120
In place of Dr. McClellan, President Bush appointed Dr. Lester M. Crawford to serve as Acting
Commissioner of the FDA.121 With a Doctor of Veterinary Medicine degree and a Ph.D in
122 Food & Drug Admin., Lester M. Crawford – Biography, http://www.fda.gov/oc/crawford/bio.html (last accessed June
19, 2006).
123 Henry Kaiser Fam. Found., FDA Commissioner Crawford Resigns, kaisernetwork.org (Sept. 26, 2005),
http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=3&DR_ID=32750.
124 Food & Drug Admin., FDA Takes Action on Plan B - Statement by FDA Commissioner Lester M. Crawford,
http://www.fda.gov/bbs/topics/NEWS/2005/NEW01223.html (last accessed June 5, 2006).
125 Ayelish McGarvey, Plan B for Plan B, THE NATION (JULY 18, 2005), available at
http://www.thenation.com/doc/20050718/mcgarvey.
126 Harris, supra note 112, at A18.
127 Henry Kaiser Fam. Found., supra note 123. Financial forms from the Department of Health and Human Services
showed that in 2004, either Dr. Crawford or his wife, sold shares in companies regulated by the FDA when Dr. Crawford
was Deputy or Acting Commissioner. Wikipedia, Lester Crawford – Biography, supra note 121. See also Letter from
Waxman, infra note 161 (on “political double-cross).
128 Transcript Deposition Lester M. Crawford 211:1- 216:3 (May 24, 2006).
129 Int’l Women’s Health Coal., Bush’s Other War: The Assault on Women’s Sexual and Reproductive Health and
Rights, http://www.iwhc.org/resources/bushsotherwar/othernominations.cfm (last accessed June 20, 2006).
130 See Press Release, Planned Parenthood website, Re-Appointment of Dr. David Hager To FDA Committee Is Bad
Medicine, http://www.plannedparenthood.org (search “Dr. David Hager,” then “Re-Appointment of Dr. David Hager
To FDA Committee Is Bad Medicine” hyperlink) (June 28, 2004).
131 Int’l Women’s Health Coal., supra note 129.
132 Planned Parenthood website, supra note 130.
1 3 3 Ka r e n T u mu l t y , J e s u s a n d t h e F D A , T I M E , O c t . 5 , 2 0 0 2 , a va i la b le a t
http://www.time.com/time/nation/printout/0,8816,361521,00.html.
134 Id.
135 See Heather Boonstra, Critics Charge Bush Mix of Science and Politics is Unprecedented and Dangerous, 6
Guttmacher Rep. Pub. Pol’y 1, 2 (May 2003), http://www.guttmacher.org/pubs/tgr/06/2/gr060201.pdf.
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pharmacology,122 many lawmakers questioned Dr. Crawford’s qualifications to lead an agency as
powerful as the FDA. At the very least, Dr. Crawford’s tenure at the FDA was considered “stormy.”123
With the August 26, 2005 announcement that the FDA was delaying its decision on Plan B
OTC status,124 Dr. Crawford earned the ire of both politicians and the public.125 Additionally, his
controversial 2005 confirmation process for FDA Commissioner reeked of what has been labeled a
“political double-cross.”126 Two months after his confirmation, on September 26, 2005, Dr. Crawford
suddenly resigned amid allegations of financial improprieties.127 In a court ordered deposition given
May 24, 2006, Dr. Crawford denied that his resignation was in any way related to the FDA’s handling
of Plan B.128
Another colorful Bush appointee to the FDA was Dr. W. David Hager, who was appointed to
the Reproductive Health Drugs Advisory Committee on December 24, 2002.129 Although the move was
publicly criticized,130 Dr. Hager was asked to serve a second term in June 2004.131 Opposition was
voiced by the Planned Parenthood Federation of America Nation Medical Committee Chairman, Dr.
Scott Spear, who stated, “Americans rely on the FDA as a trusted and objective safeguard. President
Bush has betrayed the public trust by installing a biased ideologue in a key scientific role.”132
Crawford was originally appointed by FDA Senior Associate Commissioner, Linda Arey
Sklandany, a former lobbyist with ties to the Bush family.133 Skladany rejected at least two nominees
that had been suggested by staff members of the FDA.134 In a sly move to avoid a potential
Congressional block of his appointment, Dr. Hager was appointed as a panel member of the Advisory
Panel on Christmas Eve 2002.135 This position, unlike a chairmanship, did not require Congressional
136 E-mail Petition on Urban Legends and Folklore: About, Petition Against Appointment of W. David Hager to the
Reproductive Health Panel, http://www.urganlegends.about.com/library/bl_w_david_hager.htm (last accessed June 21,
2006).
137 Id.
138 Int’l Women’s Health Coalition, supra note 129.
139 Id.
140 E-mail Petition on Urban Legends and Folklore, supra note 136.
141 Marc Kaufman, Abortion Foe to Be Reappointed to FDA Panel; Four Lawmakers Tell Bush That Doctor Has
Allowed His Personal Views to Overshadow Hid Duty, WASH. POST, June 29, 2004 at A6.
142 Food & Drug Admin., Transcript of Meeting, supra note 7.
143 Int’l Women’s Health Coalition, supra note 129.
144 Food & Drug Admin., Transcript of Meeting, supra note 7.
145 Id.
146 Id.
147 Id.
148 Id.
149 Gina Kolata, A Contraceptive Clears a Hurdle to Wider Access, N.Y. TIMES, Dec. 17, 2003, at A1, available at 2003
WLNR 5684983) (quoting Dr. Hager’s concern that OTC Plan B would encourage risky adolescent sexual behavior).
150 FDA Week, Clinton, Murray Ask Leavitt To Investigate Hager’s Memo on Plan B (May 13, 2005), available at 2005
WLNR 7566025.
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approval.136
Dr. Hager is a prominent obstetrician/gynecologist whose views on women and reproductive
health are considered outside the mainstream of modern reproductive ideology.137 Dr. Hager has
refused to prescribe contraception to unmarried women,138 has endorsed the concept that EC causes
abortion,139 and has counseled women to seek relief from premenstrual syndrome through prayer and
scripture.140 A former spokesman for the group that petitioned the FDA to rescind its approval of the
abortion pill, RU-486,141 Dr. Hager was also one of four members of the December 16, 2003, Advisory
Committe that voted against the recommendation for OTC approval for Plan B.142 Dr. Hager ended his
term on June 30, 2005, when he chose not to be reappointed to the Reproductive Health Advisory
Committee.143
IV. THE UPHILL BATTLE FOR OVER-THE-COUNTER PLAN B
On December 16, 2003, the FDA’s Nonprescription Drugs Advisory Committee, in conjunction
with the Advisory Committee For Reproductive Health Drugs, met to consider the application for Plan
B’s OTC status.144 Following presentations from FDA officials, arguments from open public hearings,
and analysis by the panel committee, the panel recommended the switch of Plan B from prescription
to OTC.145 The panel found the drug was safe to be administered without a physician’s supervision,
and there was no evidence of death, cardiovascular events, or increased risk of ectopic pregnancy
associated with Plan B use.146 All twenty-eight members of the committee found there was no evidence
to support stated concerns that nonprescription availability of Plan B would cause women to stop using
regular contraceptives.147 The final vote was twenty-three to four in favor of switching Plan B to OTC
status.148 After the committee meeting, one of the dissenters, Dr. Hager, commented, ‘“What we heard
today was frequently about individuals who did not want to take responsibility for their actions and
wanted a medication to relieve those consequences.”’149
Following the recommendation from the Advisory Committee, Dr. Hager, on request from an
FDA official he has refused to identify,150 wrote a minority opinion urging the FDA to reject OTC
status for Plan B based on a lack of information regarding how the drug affects females under the age
151 Letter from Galson, supra note 8.
152 Id.
153 Id.
154 Id.
155 Friedman, supra note 105.
156 Letter from Galson, supra note 8.
157 Id. But see U.S. GOV’T ACCOUNTABILITY OFFICE, infra note 165, at 18. On February 18, 2004, the review staff of
the Offices of Drug Evaluation III and V presented their conclusion to high level FDA management that data provided
evidence that there was neither an increase in risky behavior nor inappropriate use between younger adolescents and
older populations in regard to EC. Id.
158 Id.
159 Id.
160 Id.
161 Letter from Henry A. Waxman, Ranking Minority Member, to Andrew C. von Eschenbach, Acting Comm’r Food
& Drug Admin. (March 9, 2006), available at www.democrats.reform.house.gov/Documents/20060309124932-
06797.pdf.
162 Letter from forty-nine Congressmen to George W. Bush, Pres. of the U.S. (Jan. 9, 2004), available at
http://www.house.gov/pence/rsc/doc/weldon-morningafterpill.pdf.
163 Id.
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of sixteen.151 The Barr application for the OTC switch contained data on only twenty-nine patients
aged fourteen to sixteen and no data on patients under the age of fourteen.152 In response to this
concern, on March 11, 2004, Barr amended their application for Plan B OTC status proposing a dual
label.153 Plan B would be available without a prescription for women aged sixteen years and older,
while women under the age of sixteen would require a prescription.154
Despite recommendations by both the Advisory Committee and the Offices of Drug Evaluation,
and the support of the American Medical Association, ACOG, and the American Academy of
Pediatrics,155 the FDA took the unprecedented action of rejecting the recommendations and denying
Plan B OTC marketing status.156 In a letter released May 6, 2004, Dr. Steve Galson, Acting Director
of the CDER, denied Plan B OTC status asserting that Barr had “not provided adequate data to support
a conclusion that Plan B can be used safely by young adolescent women for emergency contraception
without the professional supervision of a practitioner . . . .”157
The letter further outlined the safety and labeling requirements necessary to obtain application
approval. In particular, Dr. Galson requested further data that would support a conclusion that
adolescent women, without the supervision of a licensed medical practitioner, could safely use Plan
B.158 Alternatively, Dr. Galson stated that Barr Laboratories could provide additional information in
support of the proposed dual labeling amendment.159 Specifically, Barr would have to provide details
on the marketing strategy for implementing a simultaneous prescription and non-prescription program
for Plan B.160 In July 2004, Barr submitted an amended application with age restrictions.161
Criticism that the FDA had succumbed to political pressure rather than adhering to sound
medical principles surfaced immediately following release of the Plan B Not-Approvable letter. Rooted
in this criticism was the knowledge that on January 9, 2004, a group of forty-nine conservative
Congressmen wrote President Bush requesting rejection of the FDA Joint Advisory panel
recommendation for Plan B OTC availability.162 The Congressmen specifically noted their concerns
regarding unsupervised Plan B availability and the effect on female adolescent sexual behavior.163
Responding that Dr. Galson appeared to be setting a different standard for evaluating Plan B
than had been applied to other contraceptives, John Jenkins, director of the FDA’s Office of New
Drugs, stated, ‘“[t]he agency has not [previously] distinguished the safety and efficacy of Plan B and
164 Marc Kaufman, Staff Scientists Reject FDA’s Plan B Reasoning, WASH. POST, June 18, 2004, at A02.
165 U.S. GOV’T ACCOUNTABILITY OFFICE, FOOD & DRUG ADMIN.,DECISION PROCESS TO DENY INITIALAPPLICATION FOR
OVER-THE-COUNTER MARKETING OF THE EMERGENCY CONTRACEPTIVE DRUG PLAN B WAS UNUSUAL, What GAO
Found, GAO Highlights, available at http://www.gao.gov/new.items/d06109.pdf.
166Transcript Deposition Steven Galson, April 26, 2006, at 186:17-20, available at
http://www.crlp.org/pdf/crt_Galson1.TR.1.pdf.
167 Id. at 186:20-22 to 187:1-4.
168 Id. at 187:8-13.
169 Press Release, Senator Hillary Rodham Clinton, Colleagues Call for “Plan B” Probe (June 16, 2004), available at
http://clinton.senate.gov/~clinton/new/2004/2004618858.html.
170 U.S. GOV’T ACCOUNTABILITY OFFICE, supra note 165, at 19.
171 Id. at 19-20.
172 Id. at 20-21.
173 Id. at 21-22.
174 Id. at 22-25. In addition, the report acknowledged that the FDA did not identify any issues that would call for age
restrictions. Id. at 30 - 31. There are no age restrictions for any of the prescription or OTC contraceptives that have been
approved by the FDA, and pediatric studies have not been required for any of them. Id.
175 Complaint, Tummino v. Crawford, available at http://www.crlp.org/pdf/crt_02105_fdacomplaint.pdf; see also
Tummino v. Von Eschenbach, 427 F. Supp. 2d 212 (E.D.N.Y. 2006) (the lawsuit parties have changed as Dr. von
Eschenbach is the current Acting Commissioner of the FDA).
176 Complaint, Tummino v. Crawford, supra note 175.
177 Id.
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other forms of hormonal contraception among different age groups of women of childbearing potential,
and I am not aware of any compelling scientific reason for such a distinction in this case.”’164 In the
past ten years, Plan B is the only drug which the FDA has rejected advisory committee
recommendations and refused approval for OTC status.165
In an April 2006 deposition of Dr. Galson, the doctor acknowledged that although he had not
yet made a firm decision, his inclination was to recommend OTC status for Barr’s amended application
for Plan B OTC status.166 Dr. Galson conceded that, “Dr. Crawford, who was the Acting Commissioner
then, told me that he was concerned about where we were heading because he knew that I was heading
towards this recommendation, and he told me that he was going to make the decision on what to do
with the application.”167 Essentially, Dr. Crawford removed Dr. Galson’s authority to make the
application decision. Dr. Galson acknowledged that he had never had an application taken from him
before on a comparable decision nor did he know of this happening to anyone else in his position.168
Responding to the FDA’s handling of the Plan B application, Senator Hillary Clinton wrote a
letter, co-signed by twenty-three Senators, requesting a Senate investigation and General Accountability
Office (GAO) inquiry into the FDA’s action.169 In November 2005, the GAO released its findings that
the process denying OTC marketing status for the initial manufacturer’s application of Plan B was
“unusual” on four accounts.170 First, the directors who would normally sign the Plan B decision letter
disagreed with the conclusion and did not sign the disapproval letter.171 Second, high level management
was involved more than it had been in other OTC switches.172 Third, there are conflicting reports as
to when the decision to deny the application was made.173 Finally, the rationale for rejection of the
OTC switch was novel and nontraditional.174
On January 21, 2005, the Center for Reproductive Rights filed a lawsuit in federal court against
Lester Crawford, Acting Director of the FDA, challenging the FDA denial for the Plan B switch.175 In
Tummino v. Crawford,176 the plaintiffs claimed that the Plan B denial violated their privacy and equal
protection rights under the Fifth Amendment, that it exceeded the statutory authority of the FDA, and
that it is “arbitrary, capricious, [and] an abuse of discretion . . . .”177 In February 2006, the FDA failed
178 Tummino v. von Eschenbach, 427 F. Supp. 2d 212, 215 (E.D.N.Y. 2006).
179 On March 14, 2006, the State of Wisconsin joined the lawsuit as an intervening plaintiff claiming the State had
concrete and substantial interests in protecting the health and welfare of its citizens. Complaint of Intervening Plaintiff,
State of Wisconsin, Tummino v. Von Eschenbach, 2006 WL 1019512. In a request for relief, Wisconsin asked that the
Commissioner of the FDA switch Plan B to OTC status and declare unlawful the FDA’s action of not having switched
Plan B to OTC status. Id.
180 Henry Kaiser Fam. Found, Democratic Senators to Block Vote on FDA Commissioner Nomination Over Agency’s
Delayed Decision on Emergency Contracep t ion, ka iserne twork.org (Apr . 7 , 2005) ,
http://www.kaisernetwork.org/daily_reports/rep_index.cfm?DR_ID=29182.
181 Marc Kaufman, FDA Expects to Ease Plan B Availability, WASH. POST, Mar. 18, 2005, at A10..
182 Letter from Michael O. Leavitt, Sec’y of Health & Hum. Services, to Michael Enzi, Chairman, Comm. on Health,
Educ., Labor & Pensions (July 13, 2005), http://murray.senate.gov/healthcare/HHS-letter.pdf.
183U.S. Senate, Vote Summary on the Nomination (Confirmation Lester M. Crawford, of Maryland, to Be Commissioner
of Food and Drugs), http://www.senate.gov/legislative/LIS/roll_call_lists/vote_menu_109_1htm (last accessed June 22,
2006); see also Press Statement, Senator Hillary Rodham Clinton, Murray, Clinton Declare Victory in Fight Over Plan
B, http://clinton.senate.gov/news/statements/details.cfm?id=240700&& (Senators Murray and Clinton declaring victory
in their efforts to force a decision on Plan B).
184 Letter from Waxman, supra note 161.
185 Letter from Lester M. Crawford, Comm’r of Food & Drugs, Food & Drug Admin., to Joseph A. Carrado, Senior Dir.,
R e g . A f f a i r s , D u r a m e d R e s e a r c h I n c . , N D A 2 1 0 0 4 5 / S - 0 1 1 , a v a i l a b l e a t
http://www.fda.gov/bbs/topics/news/2005/duramed_ltr.html.
186 Id.
187 Id.
188 Henry Kaiser Fam. Found., Leavitt Defends FDA’s Decision to Delay Action on Nonprescription Salef of Plan B,
Says ‘Yes or No’ Answer No t Gu a ranteed , ka iserne twork.o rg (Aug. 30 , 2005) ,
http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=2&DR_ID=32291.
189 Letter from Waxman, supra note 161.
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in its bid to quash plaintiffs’ discovery requests,178 and the case is currently awaiting trial.179
The FDA’s denial of OTC status triggered a political sparring match between Democrats and
Republicans. Angered by the FDA’s delay on Plan B, Senators Hillary Clinton and Patty Murray
threatened to place a hold on President Bush’s nomination of Lester Crawford for FDA Commissioner
until action was taken on the drug.180 Pressed on the issue of Plan B in the confirmation hearings, Dr.
Crawford responded that’ “[t]he science part is generally done. We’re just now down to what the label
will look [like]. This is going to be a very unusual sort of approval.”’181
Fearing that Dr. Crawford would not receive confirmation, Michael Leavitt, Secretary of HHS,
wrote a letter to Senator Michael Enzi, Chairman of the Committee on Health, Education, Labor, and
Pensions, stating that the FDA indicated they would act on the resubmitted Plan B application by
September 1, 2005.182 Assured of a date of action, the senators lifted their hold, and on July 18, 2005,
Dr. Crawford was confirmed.183
Then, in what many consider a political double cross,184 the FDA announced another delay.
Although Dr. Crawford acknowledged the amended SNDA constituted a complete response to the May
6, 2004 Not Approvable action letter,185 and the CDER had concluded data supported the safe use of
Plan B as an OTC product for women seventeen years of age and older,186 the FDA was unable to reach
a decision regarding Plan B due to marketing and packaging issues.187
HHS Secretary, Mike Leavitt, defended the decision to defer action on Plan B stating that he
promised the senators that the FDA would act by September 1, but that he had never guaranteed a “yes”
or “no” decision.188 Ranking Minority Member Henry A. Waxman wrote a series of scathing responses
stating that the FDA mischaracterized its concerns of the regulatory issues at stake.189 In the August
190 Letter from Crawford, supra note 185. Crawford maintained that the application for dual marketing presented the
FDA with three difficult and novel issues. Id. First, the Agency had never determined whether a drug could be both
prescription and OTC based on the age of the individual using the drug. Id. Second, the FDA questioned how to enforce
an age-based distinction for sale of Plan B. Id. Third, could the prescription and OTC versions of the same active
ingredient be marketed in a single package? Id.
191 Food & Drug Admin., Advance Notice of Proposed Rulemaking, 21 C.F.R. Part 310 [Docket No. 2005N-03450],
Drug Approvals: Circumstances Under Which an Active Ingredient May Be Simultaneously Marketed in Both a
Prescription Drug Product and an Over-the-Counter Drug Product (Aug. 26, 2005), available at
http://www.fda.gov/bbs/topics/NEWS/2005/cd0584.pdf.
192 Letter from Waxman, supra note 161.
193 Id.
194 Id.
195 Perspective, Susan F. Wood, Women’s Health and the FDA, 353 New Eng. J. Med. 1650, 1650 (2005).
196 Id.
197 Janice Hopkins Tanne, Another FDA Expert Resigns Over Emergency Contraception delay, 331 BRIT. MED. J. 861,
861 (2005), available at http://bmj.bmjjournals.com/cgi/reprint/331/7521/861-a.
198 Wood, supra note 195, at 1651.
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2005 announcement of the delay, the FDA claimed “difficult and novel”190 regulatory questions were
responsible for the delay and initiated a sixty day public comment period on whether the FDA should
initiate a rulemaking.191 Congressman Waxman challenged the FDA’s assertions claiming that he had
possession of previously undisclosed documents that demonstrate the FDA had been considering these
“novel” issues for at least a year before the August 2005 decision to delay.192 Senator Waxman’s
documents are purported to show that the FDA policy staff analyzed and outlined potential solutions
for the regulatory questions at least fifteen months prior to the FDA delay of action.193 In addition, the
documents indicate the FDA’s Chief Counsel had been notified of the potential regulatory issues, but
had failed to submit a determinative legal analysis.194
In protest over the FDA’s indefinite delay on a decision on Plan B, Susan F. Wood, M.D.,
Assistant Commissioner for Women’s Health and Director of the Office of Women’s Health at the
FDA, resigned her position on August 31, 2005.195 Dr. Wood stated that in delaying a decision, the
FDA was “disregarding the scientific and clinical evidence and the established review process and
were taking an action that harms women’s health by denying them appropriate access to a product that
can reduce the rate of unplanned pregnancies and the need for abortions.”196 One month later, Dr.
Frank Davidoff, former editor of the Annals of Internal Medicine and a consultant to the FDA, resigned
for identical reasons.197 As expressed by Dr. Wood, “[i]f the FDA is to continue to fulfill its important
role in public health, both in the United States and internationally, its professional and scientific staff
must maintain its independence and thus its scientific credibility.”198 Although there was room for
honest debate regarding the feasibility and enforceability of age restrictions and dual labeling, the
FDA’s unprecedented actions sullied its reputation both at home and abroad.
V. SURVEY RESULTS FROM FRANCE, THE UNITED KINGDOM,
CANADA, AND THE UNITED STATES
A. THE EFFECT OF EASILY ACCESSIBLE EMERGENCY
CONTRACEPTION ON ABORTION AND UNINTENDED
199 Adolescent Family Life Demonstration Projects, Findings and Purposes, 42 U.S.C § 300z(a)(5) (2001). Adolescent
mothers demonstrated a higher percentage of complications during pregnancy and childbirth, an increased likelihood
of not completing their education, a greater likelihood their marriage would end in divorce, and a higher risk of becoming
dependent on unemployment and welfare. Id.
200 42 U.S.C. § 300z(a)(5), supra note 199.
201 Id.
202 Camp et al, The Benefits and Risks of Over-the-Counter Availability of Levonorgestrel Emergency Contraception,
68 CONTRACEPTION 309, 309 (2003).
203 Emergency Contraception Education Act, H.R. 3326, 109th Congress (2005), available at
http://www.gov/track.us/data/us/bills.text/109/h3326.pdf (referencing the Alan Guttmacher Institute Report estimating
that 51,000 abortions were prevented in 2000 by the use of EC).
204 Chinué Turner Richardson, Advocates Again Look to States to Promote Eased Access to Emergency
Contraception, 9 GUTTMACHER POL’Y REV. 11,11 (2006), available at
http://www.guttmacher.org/pubs/gpr/09/2/gpr090211.pdf; see also Center for Reprod. Rights, infra note 267 (noting
a collaborative agreement allows a pharmacist to dispense medications through an established protocol developed
with a collaborating physician); see also discussion Part VI.
205 Barr Pharm., Inc., supra note 6.
206 See Camp et al, supra note 202 at 310.
207 Glasier et al, Advanced Provision of Emergency Contraception Does Not Reduce Abortion Rates, 69
CONTRACEPTION 361, 363-364 (2004).
208 Killick & Irving, supra note 63, at 556.
209 Id.
210 Id.
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PREGNANCY RATES
Despite various traditional health care options, unintended pregnancies are a major health care
issue across the globe. Adolescents, in particular, face profound physical, psychological, financial,
and social consequences from unplanned pregnancies.199 In addition, the offspring of teenage mothers
often face severe consequences from their adolescent parentage.200 Children of teenage mothers suffer
from a higher incidence of low birth weight and an increased mortality and morbidity rate.201
Proponents of the OTC status of Plan B claim that easier access to EC would result in a decline
in the number of abortion services and would minimize the health and societal impact of unplanned
pregnancies.202 In support of this claim, the Alan Guttmacher Institute estimated that 43% of the
decline in number of abortions in the U.S. between 1994 and 2000 could have been due to access to
emergency contraception.203 In addition (the state of Washington, where Plan B is available without
a physician’s prescription through physician collaborative agreements)204 estimated that EC saved the
state more than $22 million in Medicaid costs that would have been earmarked for pregnancy and infant
care costs.205
Although reducing the number of unplanned pregnancies and abortions is a primary goal of
OTC EC,206 there is a lack of worldwide data to support the theory that readily available EC reduces
the number of abortions.207 Although survey sample sizes have been limited, and there has probably
been an under-reporting of abortion services, the quantitative difference in abortions performed before
and after EC became available direct from the pharmacist in some countries is disappointedly small.208
For example, in a U.K. study, pharmacy direct access to EC did not correlate with a statistically
significant decrease in abortion numbers.209 Despite a 28% increase in the proportion of women
accessing EC within the first twenty-four hours of unprotected intercourse, direct pharmacy access to
Levonelle prevented what roughly equated to only five additional pregnancies for every 10,000 uses
211 Caroline Free, et al, Young Women’s Accounts of Factors Inflluencing Their Use and Non-Use of Emergency
Contraception: In Depth Interview Study, 325 BRIT. MED. J. 1393, 1394(2002); see also Jones et al, supra note 5, at 297
(noting the most common reason for contraceptive nonuse was the perception that the woman was at low risk for
pregnancy).
212 Jones et al, supra note 5, at 297.
213 Id. See also Raine et al, infra note 264 at 54 (stating the public health impact of OTC EC may be minimal due to the
high rate of unprotected intercourse and underutilization of EC).
214 See e.g. Matthew J. Seamon, Plan B for the FDA: A Need for a Third Class of Drug Regulation in the United States
Involving a “Pharmacist-Only” Class of Drugs, 12 WM. & MARY J. WOMEN & L 521, 522 (2006), available at 12 Wm.
& Mary J. Women & L. 521 (Westlaw).
215 Eric Gainer et al, Bringing Emergency Contraception Over the Counter: Experiences of Nonprescription Users in
France, Norway, Sweden and Portugal, 68 CONTRACEPTION 117, 122 (2003).
216 Id. at 121.
217 Id.
218 Boonstra, supra note 43.
219 Id.
220Laura Eggertson & Barbara Sibbald, Privacy Issues Raised Over Plan B: Women Asked for Names, Addresses, Sexual
History, 173 CAN. MED. ASS’N J. 1435, 1435 (2005); see also Henry Kaiser Fam. Found., Canadian Medical
Association Journal’s Publisher Demands Deletion of Section of Report on Nonprescription Plan B Sales,
kaisernetwork.org (Dec. 15, 2005), www.kaisernetwork.org/daily_reports/rep_indix.cfm?hint=2&DR_ID=34335. The
Canadian Medical Association, which owns the Canadian Medical Association Journal, demanded the deletion of a news
report which questioned the request for private information when purchasing Plan B. Id. Personal information, including
name and address, were being entered into a database, which is not standard practice for nonprescription drugs. Id. But
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of EC.210 Possible reasons for the small abortion reduction are varied. A likely explanation is that
many women don’t actually use the EC due to a low sense of vulnerability towards pregnancy even
though they knowingly have taken a risk.211 Additionally, women may not even recognize the
pregnancy risk.212 In a number of studies of women having abortions, a lack of reproductive knowledge
and the ensuing failure to recognize a risk of pregnancy were common reasons for not using EC.213
B. PROS AND CONS OF PHARMACY DIRECT, NON-PRESCRIPTION
ACCESS TO EMERGENCY CONTRACEPTION
It was suggested that a third class of drug regulation, a “pharmacist-only” class of drugs, would
have been a viable solution to the Plan B crisis in the U.S.214 However, in the studied countries which
have access to EC direct through the pharmacist, unique issues have arisen.
Privacy issues were raised in all the studied countries. French survey results have shown a
dissatisfaction with pharmacy direct EC that was focused around the loss of privacy in a pharmacy
environment and the perception that the personal views of pharmacists were mixing with their
professionalism.215 Although many women felt that a pharmacy offered greater privacy than a
physician’s waiting room, others reported that they were embarrassed because there was no private
counseling area.216 In addition, because the pharmacist provided the contraceptive counseling, many
women reported the pharmacist’s personal views were evident in the counseling session.217 In France,
EC that is dispensed via the schools is subject to a policy which requires in-depth counseling by the
school nurse.218 Although not mandatory, parental involvement is encouraged and may be a deterrent
to an adolescent seeking access to EC.219
In Canada, where counseling by the pharmacist is required, women have raised privacy issues
in response to the collection of personal information by pharmacists before dispensing Plan B.220
see Letter, George Murray, Privacy Issues and Plan B: The Canadian Pharmacists Association Responds, 174 CAN.
MED. J. 64, 64 (2006), available at http://www.cmaj.ca/cgi/content/full/174/1/64 (defending the request for private
information for health plan requirements).
221 Eggertson & Sibbald, supra note 220, at 1435.
222 Id.
223 Id.
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225 Schenek, supra note 58, at 37.
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Representatives on March 14, 2006 and will become effective November 1, 2006. Id. The clause specifically allows a
pharmacist to refuse to “refer to, dispense, or assist in the dispensing of any medication if there is reason to believe that
the medication would be used to cause an abortion, destroy an unborn child . . . when said referral, dispensing, or
assistance in dispensing would be contrary to the religious or moral convictions of the pharmacist . . . .” Id.
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Mandatory counseling is seen by many as a barrier to access, and the Canadian Women’s Health
Network believes Plan B should be dispensed OTC without counseling.221 In addition to the privacy
issues, counseling by pharmacists can put the cost of Plan B out of the reach of many women.
Canadian pharmacists are allowed to charge a counseling fee for Plan B, which, on average, runs
around $20.222 Combined with the cost of the medication itself, a package of Plan B obtained directly
from the pharmacist could cost over $50 – a significant obstacle for many women.223
When a medication becomes non-prescription, often the benefit of a health plan or insurance
coverage is lost. In France, EC can be obtained from a pharmacy without a physician’s prescription
for the full price of the medication, or it can be obtained under a physician’s supervision for a reduced
cost.224 This different price structure can limit financially deprived women from pharmacy access and
deprive them of the efficacy advantage of immediately accessible EC. Likewise, in the U.K., the $37
to $39 cost of Levonelle One Step represents a considerable cost barrier to students, low-income, and
unemployed women.225
In Canada, as well as the U.S., pharmacists motivated by religious or moral scruples, may
object to selling emergency contraception to their female customers.226 In November 1999, the
Canadian National Association of Pharmacy Regulatory Authorities (NAPRA) adopted a model
statement clarifying a pharmacist’s rights and obligations.227 Essentially, a pharmacist is permitted to
object to certain pharmacy services if it conflicts with the pharmacist’s view of morality or he believes
his conscience will be harmed by the service.228 The affected pharmacist must arrange an alternate
source for the customer to obtain the needed service.229
Currently, U.S. consumers may face similar issues at the pharmacy, even when they present
a valid prescription. Almost every state has a policy, a conscious clause, which allows certain health
care professionals or institutions to refuse to provide, or participate in abortion, contraceptive services,
or sterilization services.230 As of July 1, 2006, thirteen states had passed provisions that allow some
consenting pharmacist within a thirty mile radius).
232 See generally Yuliya Fisher Schaper, Emergency Contraception for Rape Victims: A New Face of the Old
Battleground of Legal Issues in the Bipartisan Abortion Politics in the United States, 29 RUTGERS L. REC. 1, 10-11
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saying that they could no longer justify not selling Plan B).
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health care professionals to refuse to participate specifically in contraceptive related services.231
Further obstacles block EC access. Catholic hospitals have not only refused to dispense
emergency contraception following cases of sexual assault, but even refused to educate the victimabout
the availability of EC.232 In addition, certain pharmaceutical chains have opted out of stocking EC. On
February 7, 2006, three women, who were unable to fill their Plan B prescriptions at Wal-Mart
pharmacies,233 filed a lawsuit claiming Wal-Mart violated a Massachusetts regulation requiring
pharmacies to stock the medications that are routinely prescribed and are necessary to meet the needs
of the community.234 After a unanimous ruling by the Massachusetts Board of Registration in
Pharmacy requiring Wal-Mart to stock Plan B in Massachusetts, the retailer announced it would stock
the product in all stores.235
State regulators have stepped in to try to increase EC availability. For example, in 2003, New
York City enacted a measure that prohibited city agencies from contracting with hospitals that did not
dispense EC or provide counseling about the availability of EC to victims of rape.236 Another measure
was passed which required pharmacies to post a sign to inform the public if they did not carry
emergency contraception.237 The state’s job of balancing a pharmacist’s conscience with a woman’s
constitutional right to contraception has been a difficult act to perform.238
C. THE EFFECT OF EMERGENCY CONTRACEPTION ON
ADOLESCENT SEXUAL BEHAVIOR
Adolescents should be an important target group for emergency contraception based on their
high rate of unintended pregnancy.239 Seventy-four to ninety-five percent of teen pregnancies are
240 Id.
241Susheela Sing & Jacqueline E. Darroch, Adolescent Pregnancy and Childbearing: Levels and Trends in Developed
Countries, 32 FAM.PLAN.PERSP. 14, 16 (2000); see also Christine Panchaud et al, Sexually Transmitted Diseases Among
Adolescents in Developed Countries, 2 FAM. PLAN. PERSP. 24, 30-32 (2000) (noting STD’s disproportionately affect
adolescents in comparison to other age groups).
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unintended, and in the year 2000, approximately 840,000 U.S. women, aged fifteen to nineteen, became
pregnant.240 Pregnancy rates and rates of STD’s are higher for adolescent females in this age group in
the U.S. than for those in the other studied countries.241
Although the FDA cited an absence of data on young adolescents to justify its Not Approvable
decision for Plan B OTC status,242 studies have shown that young adolescents behaved no differently
in response to increased access to EC than other age groups.243 In general, survey data in all four studied
countries indicated that non-prescription availability of EC did not promote risky adolescent behavior
at all. Evidence showed that women with easier access to EC did not abuse the method, did not
abandon regular contraception in favor of EC, and did not engage in increased risk-taking activities.244
In France, survey results showed that EC use increased considerably during the five years
following the introduction of Norlevo available directly from a pharmacist.245 At the end of 1999 (six
months after Norlevo became available non-prescription), 9.8% of women surveyed, aged fifteen to
forty-four years, had used an EC.246 This percentage rose to 16.9% five years later.247 Women took
advantage of the non-prescription availability of EC, for 85% of those in the survey who used EC in
2004 obtained it directly from the pharmacist.248 Overall, while there has been no significant change
in the use of regular contraception in France, the pattern of contraceptive use has changed.249 The use
of reversible methods of contraception (condoms, withdrawal, abstinence, and spermicides) have
dropped, while the use of modern contraceptive methods (pill, IUD, and sterilization) have increased.250
Rather than becoming a substitute for regular contraception, many women have reported an increased
motivation to be more vigilant with regular contraceptive use and involve their partner in contraceptive
decisions.251
In addition, there has been no indication that sexual risk taking has increased.252 An increase
in access to EC did not result in a decrease in the age of first intercourse, an increase in the proportion
of women who had ever had intercourse, or a significant increase in those at-risk for unintended
pregnancies.253
Although the proportion of U.K. women using EC has not changed since Levonelle was made
available directly from pharmacies in January 2001, the location where women obtain EC has changed
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markedly.254 The proportion of women reporting that they obtained EC from a pharmacist rather than
a health care provider increased to from 19.7% in 2001 to 32.6% in 2002.255 Furthermore, studies did
not demonstrate that women discarded regular, more effective, methods of birth control in favor of
EC.256 In fact, in a study comparing EC users in the U.S. to those in the U.K., the U.K. participants
were more likely to be using regular contraception than their American counterparts.257 In addition,
studies have concluded that repeat use of EC is rare.258
As in France, Canadian research has shown that the number of EC prescriptions sought by
women has dramatically increased since the medication became available directly through the
pharmacy.259 In a British Columbia survey, EC prescriptions increased by 102% in a five year period
in comparison to the pre-policy mean.260 Furthermore, repeat use of EC was infrequent.261 Only 2.1%
of EC users required EC three or more times during the study period.262 This finding was consistent
with a British study in which only 4% of the women studied used EC’s more than twice per year.263
Comparable with the French, U.K., and Canadian studies, U.S. studies have demonstrated that
EC use is not associated with increased risk taking behaviors among adolescent women.264 Studies
have verified that increased access to EC does not result in a substitute of EC for routine contraception,
an increase in number of sexual partners or unprotected intercourse, or an increase in the frequency of
STD’s.265 Studies have also demonstrated that adolescents were equally capable as adults in taking EC
corrrectly.266 In fact, in one study, adolescents under the age of sixteen years showed the highest
comprehension in an age-based comprehension comparison.267 Likewise, in a previous observational
study which examined the understanding of thirteen to sixteen year olds on correct use of EC, how EC
affected the menses, and common adverse side effects, the comprehension of the adolescent group was
consistent with that of the adult women.268 These survey results suggest that adolescents should not
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be restricted from OTC Plan B use due to fears about their inability to use the product correctly or
concerns about unknown side effects.269
VI. ALTERNATIVES TO FEDERAL REGULATION OF PLAN B
Although scientific studies and medical evidence showed that Plan B was effective, safe, and
did not contribute to risky sexual behavior, the FDA blocked every attempt at OTC approval. As a
result, advocates of OTC status doubled their efforts at the state level to try to circumvent federal
regulations and provide timely access to EC. At the heart of the effort was the state collaborative
practice law.270 Collaborative practice laws allow pharmacists to prescribe certain medications directly
in the pharmacy setting via an agreement with a collaborating physician.271
Washington State was the first to act by launching the Emergency Contraception Collaborative
Agreement Pilot Project in an effort to increase women’s awareness of EC and make it available
directly from a pharmacist.272 Under the agreement, pharmacists were able to dispense EC to women
who met the screening criteria established through collaborative physician protocol.273 The pilot
project was highly successful and pharmacy direct EC access continues today. The Washington
program has served as a model to other states.274 To date, nine states (Alaska, California, Hawaii,
Maine, Massachusetts, New Hampshire, New Mexico, Vermont, and Washington) have policies in
force that specifically allow a pharmacist to dispense EC to reproductive women of all ages without
a physician’s prescription.275 More states have considered similar legislation,276 but only time will tell
the effect that the recent passage of age-restricted OTC Plan B will have on these plans.
Because of the political make-up of some states, the likelihood of enacting a collaborative
practice agreement for Plan B is slim, and advocates look at different avenues. Grassroot campaigns
have sprung up across the country to raise public awareness of emergency contraception and to ensure
physicians are prescribing the drug and pharmacies are stocking it.277
The “Back Up Your Birth Control” campaign was begun five years ago to ‘“raise awareness
and position emergency contraception as a commonsense back-up method . . . .’”.278 Activists promote
EC by distributing educational materials to pharmacists in training and promote public education
through information packs printed in both English and Spanish.279 Similarly, the “Pharmacy Access
Partnership” is an organization aimed at improving women’s access to EC by “promoting
communication, leveraging resources, and building an understanding of options for change at the state
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and national level.”280 The Pharmacy Access Partnership created the website, www.GO2EC.org, that
provides a forum for pharmacists and health care advocates to share resources and ideas for improving
EC access.281
The most recent grassroots campaign aimed at improving EC awareness is the ACOG program
called “Ask Me.”282 The campaign is directed at educating the public about EC and encouraging
women to get an advanced prescription for Plan B from their health care provider.283
Campaign materials describing Plan B are provided for viewing in physician examination and waiting
rooms, and the “Ask Me” button, worn by the physician, is supplied to promote dialogue about EC
between the patient and her health care provider.284
The internet has also provided a new avenue for EC access. Princeton University launched a
website entitled Not-2-Late.com that allows women to search for Plan B providers via zip code, area
code, or city and state.285 In addition, for a $24.95 fee, Getthepill.com will provide prescriptions for
Plan B to be submitted to a pharmacy of one’s choice.286
Easier access to Plan B whether by physician, pharmacist, or OTC will not be effective in
reducing unintended pregnancies if the public is not aware of the availability of the product. Many
women have never heard of emergency contraception, and many health care providers do not prescribe
it287. Even if women have heard of Plan B, they often confuse it with the abortion pill, RU-486
(mifepristone).288
Once people understand what emergency contraceptive is, and its mode of action, the majority
are overwhelmingly supportive.289 In a 2002 survey, two-thirds of those surveyed felt government
involvement in order to reduce unintended pregnancies was a good idea.290 Furthermore, three-fourths
supported legislation aimed at improving public health knowledge.291 On July 18, 2005, Representative
Louise Slaughter introduced the “Emergency Contraception Education Act” proposing a ten million
dollar yearly budget to develop and distribute information to the public regarding emergency
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contraception.292 The bill has been referred to the House Subcommittee on Health on July 29, 2005.293
As of this date, no action has been taken.
VII. CURRENT STATUS OF PLAN B
While the lawsuit, Tummino, awaits trial, the political/scientific sparring over Plan B has
continued. On July 31, 2006, one day before Dr. von Eschenbach’s Senate confirmation hearings for
FDA Commissioner, the FDA announced that it was proceeding to resolve the Plan B issue294 (five
years after the initial application). In a July 31, 2006, letter to Duramed Research, Inc. (a subsidiary
of Barr), Dr. von Eschenbach requested a prompt meeting to discuss the sNDA for Plan B.295 Dr. von
Eschenbach wrote that in order to obtain FDA approval, the sNDA would need to be amended to seek
Plan B OTC status for women ages eighteen and over (in lieu of ages sixteen and over as in the
previous amended application).296 In addition, new packaging proposals and information regarding
Barr’s proposed marketing, education, distribution, and monitoring of OTC Plan B would be
required.297
The Senate reacted skeptically to Dr. von Eschenbach’s Plan B proposal although the doctor
maintained that the decision to revive consideration of Plan B was made “not on a political ideology,
but on a medical ideology.”298 Senators Clinton and Murray vowed to block his nomination until a final
decision was made on Plan B.299
On August 24, 2006, the FDA announced approval for OTC access for Plan B for women
eighteen years of age and older.300 Plan B will remain a prescription medication for those seventeen
years and younger.301 Senators Clinton and Murray announced they would lift their hold on Dr. von
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Eschenbach’s confirmation.302
CONCLUSION
It is naive to think the FDA can operate in a vacuum. After all, it is housed in the nation’s
capitol in the midst of the political forces which shape this country. Congress has approved
regulations that give the President the power to appoint those who agree with his political, religious,
and philosophical ideology. Therefore, it has fallen upon the people and the states to enact policies
which can keep this kind of Presidential power in check.
The FDA has a stated mission to protect and advance public health for all its citizens, but in
regard to Plan B, it has fallen far short of this mission. On December 16, 2003, a joint committee of
medical and scientific experts voted twenty-three to four to approve OTC status for Plan B. The
committee found Plan B to be safe, effective, and suitable for woman of all ages. In an unprecedented
move, FDA executives discarded the recommendation and issued a Not Approvable letter for Plan B,
citing concerns about its affect on young adolescents. Amending the sNDA to address these concerns,
Barr resubmitted the application and requested a dual label with age restrictions for Plan B OTC access.
The FDA again rejected the application citing difficulties in marketing, labeling, and enforcement.
Survey results from countries such as France, the U.K., and Canada have confirmed that EC
can be administered safely without a physician’s supervision, and that readily accessible EC does not
promote risky or promiscuous behavior. Although the FDA Advisory Committee experts agreed that
Plan B was safe for women of all ages, and OTC status for Plan B is supported by the American
Academy of Pediatrics, the FDA held fast to the idea of age restrictions. In fact, in his latest letter to
Barr Laboratories, Dr. von Eschenbach demanded a higher age restriction than had ever been previously
proposed. This new age restriction will restrict access to those who need it most – our nation’s
adolescents.
It was not coincidence that the Plan B application sat dormant until Senate confirmation
hearings for the FDA Commissioner began in July 2006. Political games continued to be played as the
Senate vowed to block a confirmation vote on Dr. von Eschenbach until a decision was reached on Plan
B. The hold on Dr. von Eschenbach’s confirmation was released as soon as the FDA released their
decision. Unfortunately, the losers of this game have been the women of this country whose rights to
reproductive health and choice have been jeopardized, and the unborn children whose very lives have
likely been affected. It has never been the responsibility of the FDA to dictate the moral fiber of the
citizens of the U.S. It is time for the religious philosophy of government and FDA officials to defer
to sound medical and scientific judgment. Although the recent FDA approval for Plan B for ages
eighteen and older is a step in the right direction, OTC approval for Plan B for women of all ages is
long over-due.
